Skip to main
INSM
INSM logo

Insmed (INSM) Stock Forecast & Price Target

Insmed (INSM) Analyst Ratings

Based on 15 analyst ratings
Buy
Strong Buy 60%
Buy 33%
Hold 7%
Sell 0%
Strong Sell 0%

Bulls say

Insmed Inc is experiencing a positive outlook driven by the increased revenue estimates for its products, notably raising the 2033E POS-adjusted worldwide Brinsupri NCFB sales estimate to approximately $8.5 billion from $7.3 billion. The company is expanding its revenue forecast by including projections for Treprostinil Palmitil Inhalation Powder (TPIP) for idiopathic pulmonary fibrosis (IPF) and demonstrating heightened confidence in its long-term product pipeline. Additionally, a decrease in the terminal decline rate in discounted cash flow calculations reflects improved expectations for the sustainability of revenue streams from Insmed’s therapeutic offerings.

Bears say

Insmed Inc faces significant challenges that contribute to a negative outlook, primarily due to potential delays in enrolling and completing necessary clinical studies for its products, including ARIKAYCE, Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP). Such delays could substantially lower the probability of success estimations for these drugs, leading to detrimental effects on the company's overall valuation. Additionally, regulatory hurdles anticipated for TPIP may prevent its entry into the idiopathic pulmonary fibrosis (IPF) market until as late as 2034, further compounding the company's growth concerns and financial outlook.

Insmed (INSM) has been analyzed by 15 analysts, with a consensus rating of Buy. 60% of analysts recommend a Strong Buy, 33% recommend Buy, 7% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Insmed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Insmed (INSM) Forecast

Analysts have given Insmed (INSM) a Buy based on their latest research and market trends.

According to 15 analysts, Insmed (INSM) has a Buy consensus rating as of Nov 11, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $177.53, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $177.53, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Insmed (INSM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.